Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23) – Pipeline Review, H2 2016’, provides in depth analysis on Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23) targeted pipeline therapeutics.

The report provides comprehensive information on the Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23)

The report reviews Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics and enlists all their major and minor projects

The report assesses Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Astex Pharmaceuticals Inc

ChoDang Pharm Co Ltd

Presage Biosciences, Inc.

Tiziana Life Sciences Plc

Tragara Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC

2.7.11.22 or EC

2.7.11.23) Overview 7

Therapeutics Development 8

Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC

2.7.11.22 or EC

2.7.11.23) - Products under Development by Stage of Development 8

Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC

2.7.11.22 or EC

2.7.11.23) - Products under Development by Therapy Area 9

Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC

2.7.11.22 or EC

2.7.11.23) - Products under Development by Indication 10

Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC

2.7.11.22 or EC

2.7.11.23) - Pipeline Products Glance 12

Late Stage Products 12

Early Stage Products 13

Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC

2.7.11.22 or EC

2.7.11.23) - Products under Development by Companies 14

Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC

2.7.11.22 or EC

2.7.11.23) - Products under Development by Universities/Institutes 16

Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC

2.7.11.22 or EC

2.7.11.23) - Therapeutics Assessment 18

Assessment by Monotherapy/Combination Products 18

Assessment by Mechanism of Action 19

Assessment by Route of Administration 20

Assessment by Molecule Type 22

Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC

2.7.11.22 or EC

2.7.11.23) - Companies Involved in Therapeutics Development 23

Astex Pharmaceuticals Inc 23

ChoDang Pharm Co Ltd 24

Presage Biosciences, Inc. 25

Tiziana Life Sciences Plc 26

Tragara Pharmaceuticals Inc 27

Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC

2.7.11.22 or EC

2.7.11.23) - Drug Profiles 28

AT-7519 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

CD-650 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

milciclib - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Small Molecule to Target Cdk2, Cdk4, Cdk6, Cyclin D1, Cyclin B1, Cdc2, p53 and p16 for Bacterial Infections and Oncology - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Small Molecules to Inhibit CDK1, CDK5 and GSK3b for Alzheimer's Disease - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

TG-02 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

voruciclib - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC

2.7.11.22 or EC

2.7.11.23) - Dormant Projects 41

Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC

2.7.11.22 or EC

2.7.11.23) - Discontinued Products 43

Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC

2.7.11.22 or EC

2.7.11.23) - Featured News & Press Releases 44

Jun 03, 2016: Presage Biosciences Appoints David Johnson to Board of Directors 44

Apr 19, 2016: Presage Biosciences Presents Data Demonstrating Tumor Growth Inhibition by Voruciclib and Proteasome Inhibitors Superior to Single Agents in Model of Triple Negative Breast Cancer 44

Oct 28, 2014: Thymic carcinoma Phase II data of Milciclib, a kinase inhibitor discovered at Nerviano Medical Sciences, disclosed at the medical oncology meeting AIOM 2014 45

May 28, 2014: Tragara's TG02 is Highly Active in CLL Cells Derived from Patients who have Failed Treatment with Ibrutinib 46

May 14, 2014: Phase II data of Nerviano Medical Science’s kinase inhibitor Milciclib in patients with thymic carcinoma to be reported at 2014 ASCO 47

Apr 07, 2014: New Preclinical Data of Tragara’s TG02 in Acute Leukemia at AACR Meeting in San Diego 47

Dec 06, 2013: New Preclinical Data of Tragara’s TG02 in Multiple Myeloma and Leukemia to be Presented at ASH 2013 Annual Meeting 48

Dec 03, 2013: Tragara Initiates Clinical Study of TG02 in Combination with Carfilzomib in Multiple Myeloma 48

Sep 12, 2013: Tragara Announces Oral Presentation at Society of Hematology Oncology Annual Meeting 49

May 31, 2012: Tragara Describes Mechanism Of Action Of Anti-Tumor Drug TG02 49

May 22, 2012: Piramal Healthcare To Present Phase I Data For New Oral Anticancer Molecule At ASCO Annual Meeting 50

Apr 03, 2012: Piramal Healthcare To Present Preclinical Data On Tumor Drug P1446A-05 At 2012 AACR Annual Meeting 52

Apr 02, 2012: Tragara Pharma Announces Presentation Of Preclinical Data Of TG02 At 2012 AACR Annual Meeting 52

Sep 14, 2011: Tragara And Multiple Myeloma Research Foundation Initiate Phase I Clinical Study Of TG02 In Multiple Myeloma Patients 53

Mar 23, 2011: Tragara To Present TG02 Poster At 102nd AACR Annual Meeting 54

Appendix 55

Methodology 55

Coverage 55

Secondary Research 55

Primary Research 55

Expert Panel Validation 55

Contact Us 55

Disclaimer 56

List of Tables

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Products under Development by Companies, H2 2016 15

Number of Products under Investigation by Universities/Institutes, H2 2016 16

Products under Investigation by Universities/Institutes, H2 2016 17

Assessment by Monotherapy/Combination Products, H2 2016 18

Number of Products by Stage and Mechanism of Action, H2 2016 19

Number of Products by Stage and Route of Administration, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 22

Pipeline by Astex Pharmaceuticals Inc, H2 2016 23

Pipeline by ChoDang Pharm Co Ltd, H2 2016 24

Pipeline by Presage Biosciences, Inc., H2 2016 25

Pipeline by Tiziana Life Sciences Plc, H2 2016 26

Pipeline by Tragara Pharmaceuticals Inc, H2 2016 27

Dormant Projects, H2 2016 41

Dormant Projects (Contd..1), H2 2016 42

Discontinued Products, H2 2016 43

List of Figures

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Top 10 Indication, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 18

Number of Products by Stage and Mechanism of Actions, H2 2016 19

Number of Products by Routes of Administration, H2 2016 20

Number of Products by Stage and Routes of Administration, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 22

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports